Marine carbohydrates move from lab curiosity to clinical candidates

A new review in Glycoscience & Therapy maps how marine-derived carbohydrates have progressed from early bioactivity studies to approved drugs and clinical trials. It also flags the production, quality-control and mechanism hurdles that still stand in the way of broader therapeutic use.

Why it matters: - Marine carbohydrates could expand the drug pipeline with new antiviral, anticoagulant, immunomodulatory and antitumor therapies. - The review argues that clinical translation depends not just on bioactivity, but on reproducible production, structural control and safety data. - The findings also matter for drug delivery, wound healing and tissue engineering, where marine polysaccharides can provide useful material properties.

What happened: - A review in Glycoscience & Therapy examined marine carbohydrate therapeutics from early discovery work through approved products and clinical trials. - The review traced the field from cytarabine, a marine-inspired leukemia drug approved in the United States in 1969, to later carbohydrate-based products derived from alginate, carrageenan and other marine materials. - The authors also surveyed current clinical-trial candidates for viral infections, cancer, metabolic disorders, tissue repair, cystic fibrosis and neurological disease.

The details: - Marine organisms such as algae, marine animals and microorganisms produce polysaccharides and related molecules with uncommon structures. - These molecules can feature distinctive sulfate patterns, sugar linkages and branched architectures. - Structural features such as sulfation, molecular weight, branching and monosaccharide composition can influence therapeutic activity. - Those same features can vary by species, season, extraction method and processing conditions. - The review links structure to function across approved drugs and clinical-stage candidates. - The paper also examines the production, quality-control, mechanistic and pharmacokinetic barriers that limit translation. - The article is identified by DOI 10.1016/j.glycos.2026.100047.

Between the lines: - The field has moved beyond proving that marine carbohydrates have biological effects. - The harder problem is making those molecules consistent enough for medicine, since small structural differences can change performance. - Guangli Yu, the senior and co-corresponding author, said future progress depends on reliable production methods, better structural and activity-based quality control, validated molecular targets, and stronger pharmacokinetic and safety studies. - Yu said the work will require collaboration across glycoscience, analytical chemistry, synthetic biology, materials science and clinical research.

What's next: - Researchers are likely to focus on cultivation, fermentation and enzymatic processing to produce more reliable material. - The next steps also include tighter quality control and more rigorous studies of how these carbohydrates behave in the body. - Continued clinical testing will determine which marine-derived candidates can move from promising chemistry to approved therapies.

The bottom line: - Marine carbohydrates have clear therapeutic promise, but the review shows that translation will hinge on manufacturing consistency, mechanism validation and clinical-grade safety evidence.